{"a":[{"_":"Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis","$":{"href":"/biotech/novo-walks-away-285m-pact-develop-monthly-glp-1-ascendis","hreflang":"en"}}]}

PartnershipnegativeNegative

AI Analysis

Summary

Novo Nordisk has terminated its $285 million partnership with Ascendis Pharma for the development of a monthly GLP-1 weight loss drug after less than two years of collaboration.

Outcome Details

Novo Nordisk terminated a $285 million collaboration agreement with Ascendis Pharma for the development of a monthly GLP-1 obesity drug after less than two years

Importance:7/10

Sentiment:

-0.80

GLP-1obesitypartnership_terminationcollaboration_failure

Related Companies

$NVO $ASND

Read the original article

Published by FierceBiotech on September 15, 2026 5:22 AM

Read Original